Information for doctors
Tinefcon’s successful clinical trial was carried out under exacting standards.
- A double-blind, parallel group, placebo-controlled, prospective, multi-center study in subjects with moderate to severe cases, (subjects with a PASI score > 10)
- Evaluation of adverse events, physical examination, clinically significant changes in laboratory parameters and ECG histopathological analysis and gene expression profiling carried out to support the efficacy
- Tinefcon demonstrated improvement in a number of subjects (PASI 75 response & PASI 90 response) along with an improvement in histopathology analysis
- Exhibited a promising safety profile
- Initial efficacy observed over a 3 month treatment period
- A new Phase IV follow up study launched in September 2010 with 200 patients
Download our AAD presentation Tinefcon Presentation for Doctors
Results presented toL
Congress of Psoriasis Networks, Paris, July 2010
American Academy of Dermatology, Annual Meeting, Miami, March 2010
